GBT
PRME icon

Grove Bank & Trust’s Prime Medicine PRME Stock Holding History

Grove Bank & Trust’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-77
Closed -$735 – 679
2023
Q3 		$735 Buy
+77
New +$1K ﹤0.01% 718

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Grove Bank & Trust's PRME Position: Q4 2023 in Review

Grove Bank & Trust sold out of Prime Medicine (PRME) in Q4 2023, closing a stake of 77 shares — an estimated $735 sold.

Grove Bank & Trust first reported a position in PRME in Q3 2023 and held it in 1 quarter. The position peaked at $735 in Q3 2023. 105 funds tracked by Wall St. Rank hold PRME as of Q4 2023.

  • Grove Bank & Trust reported no remaining Prime Medicine position as of Q4 2023 after selling out during the quarter.
  • Grove Bank & Trust sold 77 Prime Medicine shares in Q4 2023, an estimated $735.
  • Grove Bank & Trust first reported a position in Prime Medicine in Q3 2023 and held it in 1 quarter.
  • Grove Bank & Trust's Prime Medicine position peaked at $735 in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2023.

Based on Grove Bank & Trust's 13F filing for Q4 2023, filed 30 Jan 2024.